AcuraStem Incorporated

Return to Grants

Awards to the Institution

Program Type	Investigator	Grant Title	Award Value
Preclinical Stage Projects	Mr. Samuel V. Alworth MS, MBA	Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies	$7,500,000
Therapeutic Translational Research Projects	Mr. Samuel V. Alworth MS, MBA	Development of AS-241, an UNC13A Targeting Antisense Oligonucleotide (ASO) Treatment for ALS, for IND-enabling Studies	$4,012,325
Late Stage Preclinical Projects	Mr. Samuel V. Alworth MS, MBA	Manufacturing of AS-202, an Antisense oligonucleotides for a Phase 1/2 Clinical Trial for Amyotrophic Lateral Sclerosis	$0
			Total: $11,512,325.00